Table 1.
Clinical Trials That Have Been Reported to Date, Evaluating Dendritic Cell Vaccines in Glioma
| Reference or NCT# | N | Trial Phase | Population | Vaccine Target | Survival Data |
|---|---|---|---|---|---|
| Yu et al36 | 8 | I | Glioblastoma, anaplastic astrocytoma | Autologous tumor peptide | OS: 133 weeks |
| Kikuchi et al37 | 8 | I | 5 glioblastoma, 3 anaplastic astrocytoma | Tumor cells fused with the DC | Unclear, 1/8 patients had SD after 12 months |
| Rutkowski et al38 | 6 | I | Recurrent malignant glioma | Tumor lysates | OS in 2 patients was >35 months |
| Yamanaka et al39 | 24 | I/II | Recurrent malignant glioma, III Recurrent malignant glioma, IV | Tumor lysates | OS: 480 days |
| Okada et al40 | 22 | I/II | Glioblastoma, Anaplastic astrocytoma, Anaplastic Oligodendroglioma | EphA2, IL-13Rα2, YKL-40, gp100 | 9/22 patients were progression-free ≥12 months |
| Prins et al41 | 23 | I | Glioblastoma | Tumor lysate | OS: 31 months |
| Sakai et al42 | 10 | I | Glioblastoma, anaplastic astrocytoma, Anaplastic Oligodendroglioma | WT-1 | Unclear |
| Wen et al43 | 81 on ICT-107 vs. 43 control in a 2:1 randomization | II | Glioblastoma | ICT-107 | mOS: 17.0 months; mPFS: 11.2 months |
| Liau et al44 | 331 | III | Glioblastoma | Tumor Lysate | OS of 19.3 months |
| Parney et al45 | 21 | II | Glioblastoma | Lysates, covering EGFRvIII, erbB2, gp100, MAGE-A3, IL13Ra2 plus more. | OS 25% at 2 years |
| Batich et al46 | 11 | I | Glioblastoma | CMV pp65 DC with ddTMZ | mOS from diagnosis 41.1 months (21.6–113.3) |
| Batich et al46 | 12 | II | Glioblastoma | CMV pp65 DC with stdTMZ | mOS from diagnosis Td arm 41.4 months (20.6–∞). mOS from diagnosis unpulsed DC arm 18.5 months (13.8–41.3) |
Abbreviations: ∞, undefined; ddTMZ, dose dense 21 day temozolomide 100 mg/m2; mOS, median overall survival; mPFS, median progression-free survival; stdTMZ, standard 5 day temozolomide 200 mg/m2.